Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC
Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This is a prospective, single center phase II clinical study with a planned enrollment of 33
patients. The main objective is to evaluate the efficacy and safety of the PD-1 inhibitor
toripalimab combined with cetuximab, cisplatin, and 5-FU regimen in the treatment of locally
advanced oral squamous cell carcinoma patients who are initially unresectable.